Body weight variability and the risk of liver‐related outcomes in type 2 diabetes and steatotic liver disease: a cohort study

Abstract

AbstractObjectiveThe objective of this study was to evaluate the effects of body weight variability (BWV) on the occurrence of adverse liver outcomes in individuals with type 2 diabetes (T2D) and metabolic dysfunction‐associated steatotic liver disease (MASLD).MethodsA total of 549 patients with T2D and MASLD had BWV parameters assessed during the first 2 years of follow‐up. The associations between increasing BWV and liver outcomes (clinical cirrhosis or a liver stiffness measurement on transient elastography > 15 kPa, performed after a median of 7 years of cohort entry) were examined by multivariable logistic regressions. Interaction/subgroup analyses were performed according to participants' physical activity during the initial 2‐year period.ResultsIndividuals were followed up for an additional median 9.7 years, over which 34 liver outcomes occurred (14 with clinical cirrhosis and 20 with liver stiffness measurement > 15 kPa). A 1‐SD increase in weight SD and average real variability was associated with 52% higher (95% CI: 4%–128%) odds of having an adverse liver outcome. Otherwise, in interaction/subgroup analyses, an increased BWV was associated with a higher likelihood of outcomes only in sedentary individuals.ConclusionsIncreased BWV was associated with adverse liver outcomes in individuals with T2D and MASLD; however, in those who were physically active, it was not hazardous.